Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 4/20 | 0.33 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.32 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.32 |
| ▸ | ADK | P55263 | 1/20 | 0.32 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24305321 | 0.92 | TMPRSS2 (0.37) | P2RY10DNPH1POLRMTGPR174ADK | |
| SCHEMBL29413326 | 0.92 | TMPRSS2 (0.37) | P2RY10DNPH1POLRMTGPR174ADK | |
| SCHEMBL24304626 | 0.92 | POLRMT (0.30) | POLRMTADK | |
| SCHEMBL25970656 | 0.91 | ADK (0.37) | POLRMTADK | |
| SCHEMBL27455296 | 0.91 | ADK (0.37) | POLRMTADK | |
| SCHEMBL25969534 | 0.91 | ADK (0.37) | POLRMTADK | |
| SCHEMBL24304635 | 0.91 | P2RY10 (0.31) | P2RY10POLRMTADK | |
| SCHEMBL25973621 | 0.91 | P2RY10 (0.31) | P2RY10POLRMTADK | |
| SCHEMBL25969436 | 0.91 | P2RY10 (0.31) | P2RY10POLRMTADK | |
| SCHEMBL25970036 | 0.91 | P2RY10 (0.31) | P2RY10POLRMTADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | P2RY10 909/4885DNPH1 2577/4885POLRMT 371/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | P2RY10 909/4885DNPH1 2577/4885POLRMT 371/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | P2RY10 909/4885DNPH1 2577/4885POLRMT 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.